- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Inovio Investors Urged to Join Securities Fraud Lawsuit
The Schall Law Firm reminds investors of a class action lawsuit against Inovio Pharmaceuticals over alleged violations of securities laws.
Mar. 16, 2026 at 3:34pm
Got story updates? Submit your updates here. ›
The Schall Law Firm, a national shareholder rights litigation firm, is reminding investors of a class action lawsuit against Inovio Pharmaceuticals, Inc. (NASDAQ: INO) for alleged violations of securities laws. The lawsuit covers the period from October 10, 2023 to December 26, 2025, and investors who purchased the company's securities during that time are encouraged to contact the firm to participate in the case.
Why it matters
This lawsuit highlights the ongoing legal and regulatory challenges facing pharmaceutical companies, particularly around issues of transparency, disclosure, and investor confidence. The outcome of this case could have significant implications for Inovio's future and set precedents for how such securities fraud allegations are handled in the biotech industry.
The details
According to the complaint, Inovio made false and misleading statements to the market about manufacturing deficiencies for its CELLECTRA device, the likelihood of filing the INO-3107 BLA by 2H 2024, and the lack of sufficient evidence supporting an FDA priority review or accelerated approval for its BLA. The Schall Law Firm is representing investors in the class action lawsuit, which seeks to recover losses suffered as a result of the company's alleged misconduct.
- The class period covers October 10, 2023 to December 26, 2025.
- Investors have until April 7, 2026 to contact the Schall Law Firm to participate in the lawsuit.
The players
Inovio Pharmaceuticals, Inc.
A biopharmaceutical company focused on developing DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with HPV.
The Schall Law Firm
A national shareholder rights litigation firm that specializes in securities class action lawsuits and shareholder rights litigation.
What they’re saying
“We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge.”
— Brian Schall, Attorney, Schall Law Firm (Press Release)
What’s next
The judge in the case will decide on April 7, 2026 whether to certify the class and allow the lawsuit to proceed.
The takeaway
This lawsuit underscores the importance of transparency and accurate disclosures by pharmaceutical companies, especially those with products in development. The outcome could set a precedent for how securities fraud allegations are handled in the biotech industry going forward.
